Handouts for Patients and Families (available on the accompanying CD) are included in the index and are indicated by “CD” rather than page numbers.

AAC. See Augmentative communication system (AAC)
AAC-RERC. See Rehabilitation Engineering Research Center on AAC (AAC-RERC)
Academy of Neurologic Communication Disorders and Sciences (ANCDS), CD
Acetylcholine, 79
Acid indigestion, CD
Acquired Parkinson’s disease, 69
ACTH (adrenocorticotropic hormone), 152
ADA (Americans With Disabilities Act), 154
Adrenocorticotropic hormone (ACTH), 152
Advanced health care directive, 177
Affective disorders. See also Depression
with ALS, 8, 12, 30, 222
with multiple sclerosis, 150
AFO. See Ankle-foot orthosis (AFO)
Akinesia, 71–73
Alerting systems, 37
Alimentation, 221
Alphabet boards and alphabet supplementation, 37, 102, 131–132, 163, 221
ALS. See Amyotrophic lateral sclerosis (ALS)
ALS Association of America (ALSA), 7, CD
ALS Functional Rating Scale–Revised, 4
ALS Health State Scale, 4–5
ALS Severity Scale, 24–29, 42, 43–44, 55–57
Alternate motion rates, 177–179
American Academy of Neurology, 6, 14, 17
American Parkinson Disease Association (APDA), CD
American Speech-Language-Hearing Association (ASHA), CD
Americans With Disabilities Act (ADA), 154
Amplifier, 221
Amyotrophic lateral sclerosis (ALS)
    age at onset of, x
    alternate motion rates with, 178
    aphasia with, 20
    aspiration management and, 52–54
    aspiration pneumonia with, 184
    assessment of respiratory problems with, 14–15
    assessment of swallowing function in, 43–44
    assessment of, with ALS Severity Scale, 24–29, 42, 43–44, 55–57
    association on, CD
    benefits of early diagnosis, 6
    cause of, 3–4
    clinical stages of ambulatory function in, 9
    cognitive changes with, x, 10–12
    compared with other motor neuron diseases, 1–2
definition, 1, 221
diagnosis, 5–6
eating habits and, 45–48
emotional and psychosocial aspects of, 8, 12, 30
employment for individuals with, 40
exercise for, 7–8
frontal lobe syndrome and, 11
frontotemporal dementia (FTD)/ALS and, 11–12
gender ratio in, 2
goals of rehabilitation for, 7
grief and depression with, 8
handout, CD
hospice admission criteria for, 10
incidence of, 2
management of respiratory problems with, 15–17
medications for, x, 6–7
muscle cramping and spasms in, 8
neurological changes with, x, 2–3
palliative care for, 9–10
patient autonomy and, 8–9
rate of speech changes in, 20, 22–24
rate of swallowing disorders in, 42–43
references on, 59–67
rehabilitation medicine for, 7–10
respiratory problems with, 12–17
saliva management and, 49–52
signs and symptoms of, ix, x, 1, 2, 3, CD
speech disorders with, x, 18–41, CD
speech intelligibility related to other variables in, 20, 21–22
speech treatment for, 29–41, CD
surgery for swallowing disorders with, 52, 53–54
survival data on, 2
swallowing disorders management for, 44–49
swallowing disorders with, x, 42–54, CD
typical course of, x, 4–5
weakness and, 3, 7, 8

ANCDS. See Academy of Neurologic Communication Disorders and Sciences (ANCDS)
Ankle-foot orthosis (AFO), 221
Anticholinergic drugs, 79
APDA. See American Parkinson Disease Association (APDA)
Aphasia, 20
Arizona Battery for Communication Disorders, 149
Artane, 79
Articulation
  definition, 221
  with Parkinson’s disease, 87, 88
ASHA. See American Speech-Language-Hearing Association (ASHA)
Assessment, 221
  Diagnosis; Interviews; Speech and swallowing examination
  of amyotrophic lateral sclerosis (ALS), 24–29, 42, 43–44, 55–57
  of conversation and interaction, 198–200, 207–217
  of dehydration, 51
  Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
  of lower and upper extremity function in ALS, 27–29, 57–58
  of multiple sclerosis severity, 150–151
  of Parkinsonian dysarthria, 95, 99
  Aspiration, 221
  Aspiration management, 52–54
  Aspiration pneumonia, 184
  Aspirator, 221
of respiratory problems with ALS, 14–15, 43–44
of speech disorders (dysarthria) in ALS, 25–26, 55
of speech disorders (dysarthria) in Multiple sclerosis, 158–160
of speech function during clinical examination, 183, 187, 189–190
of swallowing function during clinical examination, 183, 187–188, 191
of swallowing function in ALS, 26–27, 42, 43–44, 56, 184
of swallowing function in Huntington’s disease, 135–137
of swallowing function in multiple sclerosis, 166
of swallowing function in Parkinson’s disease, 106–107

Assistive technology. See also Augmentative communication system (AAC)
with Huntington’s disease, 138
with multiple sclerosis, 154
Assistive ventilatory, 15–17
Associations and organizations, CD
Ataxia, 153, 157, 161–162, 221, CD
Athetosis, 71
Atrophy, 221, CD
Audio recording of conversation, 199, 208–209, 215–217
Auditory comprehension, 124

Augmentative communication system (AAC)
alerting systems and, 37
alphabet boards and alphabet supplementation, 37, 102, 131–132, 163, 221
ALS Severity Scale and, 26
for amyotrophic lateral sclerosis (ALS), 36–41
classification of functional capabilities for, 38–39
for conversations, 196–197, 201–202, 206, 208
definition, 221, CD
employment of individuals with ALS using, 40
funding of, 40–41
handout, CD
for Huntington’s disease, 130
for multiple sclerosis, 163, CD
multipurpose systems for, 37–38
for Parkinson’s disease, 102, CD
patterns of system use, 39
portable writing systems and, 37
research center on, CD
speech-language pathologists (SLPs) and, 196–197
telephone communication and, 37
timing of AAC intervention, 36

Autonomy of patients, 8–9
Avonex, 152

Basal ganglia, 70–71, 103, 122, 123, 221, CD
Behavioral rate-control techniques, 100–101
Betaseron, 152
Bilevel Positive Air Pressure (BiPAP), 16
BiPAP (Bilevel Positive Air Pressure), 16
Bolus, 221
Bradykinesia, 71–73, 221, CD
Breathiness, 221
Bromocriptine, 78
Buccal/frontal/orbital muscles, 180–181
Buccinators, 179–180, 187

Cachexia, 221
Calendars and memory aids, 132, 154
Catechol-O-methyltransferase (COMT), 79
Center for Neurologic Study—Lability Scale, 12
Centers for Disease Control, 182
Central nervous system (CNS), 147, 150, 221
Charcot’s disease. See Amyotrophic lateral sclerosis (ALS)
Choking
  first aid for, 46, CD
  multiple sclerosis and, 166
Chorea, 71, 122, 124, 221
Clinical examination. See Speech and swallowing examination
CNS. See Central nervous system (CNS)
Cognitive problems
  with amyotrophic lateral sclerosis (ALS), x, 10–11
  frontal lobe syndrome and, 11
  frontotemporal dementia (FTD)/ALS, 11–12
  with Huntington’s disease, x, 123–124, 128–130
  with multiple sclerosis, x, 148–149, 154
  with Parkinson’s disease, x, 81–82, CD
Cogwheel rigidity, 221
Communication. See Conversation and interaction
Communication Independence for the Neurologically Impaired, 38
“Computerized Speech Lab,” 162–163
COMT. See Catechol-O-methyltransferase (COMT)
Comtan, 79
Contractures, 222
Conversation and interaction
  assessment of, 198–200, 207–217
  augmentative communication system (AAC) for, 196–197, 201–202, 206, 208
  case examples, 207–208
  conversation starters for people with Huntington’s disease, 132–133
  gaining attention for, 205
  Huntington’s disease and, 124
  impact of dysarthria on, 196–197
  importance and organization of, 195–196
  interview for assessment of, 198–199, 207, 211–213
  Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
  management of, 203–209
  opportunities for, 198
  perception of current problems with, 198
  preferences and styles in, 198
  problems with, 198–199, CD
  profiles of conversation partnership, 200–207
  recording of, 199, 208–209, 215–217
  references on, 219–220
  role of speech–language pathologists in, 196–197
  showing understanding for, 205, 206
  strategies for, 199
  tips for, CD
  topic initiation and topic change for, 206
  turn design for, 206
Copaxone, 152
Cough, 14, 17, 182
Counseling. See Psychological services and counseling
Cuirass, 222

DAF. See Delayed auditory feedback (DAF)
DBS. See Deep brain stimulation (DBS)
Decomposition, CD
Deep brain stimulation (DBS), 79–80, 91
Degenerative diseases. See specific diseases
Dehydration, 51. See also Liquid intake
Delayed auditory feedback (DAF), 101, 222
Dementia
  - definition, 222
  - frontotemporal dementia (FTD)/ALS, 11–12
  - with Parkinson’s disease, 81, 82
Deprenyl, 78–79
Depression. See also Affective disorders
  - with amyotrophic lateral sclerosis (ALS), 8
  - with Huntington’s disease, 123
  - major depressive disorder (MDD), 150
  - with multiple sclerosis, 150
  - with Parkinson’s disease, 80–81, 82
Diadochokinetic rates, 160, 177–179, 222
Diagnosis. See also Assessment; Speech and swallowing examination
  - of amyotrophic lateral sclerosis (ALS), 5–6
  - of Huntington’s disease, 124–125
  - of multiple sclerosis, 150
  - of Parkinson’s disease, 73
Dietary changes
  - for gastroesophageal reflux disease (GERD), CD
  - Huntington’s disease and, 138
  - Parkinson’s disease and, 109
  - for swallowing difficulties, 27, 47–48, CD
Direct selection, 222
Disease-modifying therapy, 152
Dopamine, 222, CD
Dopamine breakdown inhibition, 78–79
Dopamine imitators, 78
Dopamine replacement, 78
Double swallow, 46
Drug management. See Medications
Durable power of attorney for health care, 222
Dysarthria. See Speech disorders (dysarthria)
Dyskinesia, 222
Dysmetria, 153
Dysphagia. See Swallowing disorders (dysphagia)
Dysphagia Severity Rating Scale, 107, 108
Dystonia, CD
Dystonic syndrome, 70–71

Eating. See Dietary changes; Feeding; Swallowing disorders (dysphagia); Tube feeding
EDSS (Expanded Disability Status Scale), 151
El Escorial criteria, 5
Eldepryl, 78–79
Emergency procedures for choking, 46, CD
Emotional lability, 12, 222. See also Affective disorders; Depression
Employment
  - compensatory techniques for individuals with multiple sclerosis in, 155
  - of individuals with ALS using AAC, 40
  - of individuals with multiple sclerosis, 154–155
Entacapone, 79
Epiglottic sew-down procedures, 17, 54
Evaluation. See Assessment; Diagnosis; Speech and swallowing examination
Exacerbations, CD
Examination. See Speech and swallowing examination
Exercise, 7–8. See also Rehabilitation
Expanded Disability Status Scale (EDSS), 151, 165
Extrapyramidal system, 222
Extremity function. See Lower extremity function; Upper extremity function
Eye-gaze systems, 41

Fasciculations, 222
Fatigue, 149, 153–155, 167
Feeding. See also Dietary changes; Swallowing disorders; Swallowing disorders management; Tube feeding
alternative feeding for people with Huntington’s disease, 138
calorie-dense foods, 47
control of eating rate and bite size, 138
definition, 222
early eating problems and ALS, 45, 46–47
multiple sclerosis and, 165
normal eating habits and ALS, 45
Parkinson’s disease and, 109
slowed eating, CD
Festination, 222
Fibrillations, 222
First aid for choking, 46, CD
Flaccid dysarthria, 223
Flaccidity, 223, CD
Food. See Dietary changes; Feeding; Swallowing disorders
Forced vital capacity (FVC), 14–15, 44, 182
Frontal lobe syndrome, 11
Frontotemporal dementia (FTD)/ALS, 11–12
FTD. See Frontotemporal dementia (FTD)/ALS
Functional status, 150–151
FVC. See Forced vital capacity (FVC)

GABA (gamma-aminobutyric acid), 122
Gag reflex, 223
Gamma-aminobutyric acid (GABA), 122
Gastroesophageal reflux disease (GERD), CD
Gastrostomy, 223
GERD. See Gastroesophageal reflux disease (GERD)
Glatiramer, 152
Grief. See Depression

Harshness, 223
HDSA. See Huntington’s Disease Society of America (HDSA)
Heat sensitivity, 150
Heimlich maneuver, CD
Hemiballismus, 71
Hoarseness, 223
Hoskins and Yahr Functional Rating Scale for Parkinson’s disease, 75–76
Hospice admission for ALS, 10
Huntington’s disease
age at onset of, x
alphabet boards for people with, 131–132
alternative feeding for people with, 138
assistive devices for people with, 138
association on, CD
augmentative communication system (AAC) for, 130
calendars and memory aids for people with, 132
cognitive problems with, x, 123–124, 128–130
definition, 121, 223
diagnosis, 124–125
dietary changes for, 138
emotional disturbances with, 123
hereditary nature of, 121, 125, 126
incidence of, 121
management of mild dysarthria and cognitive changes with, 128–129
management of moderate dysarthria and cognitive changes with, 129–130
management of severe dysarthria with, 129, 130–134
measurement of functional progression of, 125
medical management of, 126
motor disturbances with, 122–123
natural speech with supportive partners, 131
neurological changes with, x, 121–122
postural and positional changes for people with, 137–138
references on, 141–143
remotivation therapy for people with, 134
respiratory chorea with, 124
speech characteristics associated with, 127–128
speech disorders with, x, 124, 126, 127–134, CD
speech treatment for, 128–134, CD
supervision to control eating rate and bite size for people with, 138
swallowing characteristics associated with, 135, 136
swallowing disorders management for, 137–138
swallowing disorders with, x, 135–138, CD
yes/no system for people with, 133–134, 139
Huntington’s Disease Society of America (HDSA), CD
Hyperkinetic dysarthria, 86, 127, 223
Hypotonia, 223
Hypokinesia, 223

ICF. See *International Classification of Functioning, Disability and Health* (ICF)
Idiopathic Parkinson’s disease, 69
Immunomodulatory agents, 152
Incidence, definition of, 223
“Intention” tremor, 147, 153, 155
Interaction. See *Conversation and interaction*
Interferon beta-1a, 152
Interferon beta-1b, 152
*International Classification of Functioning, Disability and Health* (ICF), 130
Interviews. See also Assessment
   for assessment of Parkinsonian dysarthria, 95
   for speech assessment in multiple sclerosis, 158–159
   Swallowing Disorders Interview Worksheet, 191
   for swallowing evaluation in Huntington’s disease, 136
   for swallowing evaluation in Parkinson’s disease, 106
Jobs. See Employment
Juvenile Huntington’s disease, 122

KayPENTAX, 162
Kennedy disease, 1, 2

Language deficits. See also Speech disorders (dysarthria)
with Huntington’s disease, 123–124
management of, with Huntington’s disease, 128–133
with multiple sclerosis, 149
with Parkinson’s disease, 82
Laryngeal penetration, 223
Laryngectomy, 17, 54
Laryngotraheal separation, 17
Lee Silverman Voice Treatment (LSVT), 80, 98–99
Lentiform nucleus, 70
Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
Levodopa, 78, 79, 83, 103, 223
Lips, examination of, 177–179, 186
Liquid intake
assessment and treatment of dehydration, 51
maintenance of, 46, 47
swallowing disorders and, 46, 47–48, CD
taste, temperature, texture sensations of liquids, 47–48
washing foods down with liquids, 47
Living will, 177, 223
Lou Gehrig’s disease. See Amyotrophic lateral sclerosis (ALS)
Lower extremity function
assessment of, with ALS Severity Scale, 27–29, 57
definition, 223
Lower motor neurons, 223, CD
LSVT. See Lee Silverman Voice Treatment (LSVT)

Magnetic resonance imaging (MRI), 5, 146–147, 150
Major depressive disorder (MDD). See Depression
MAO. See Monoamine oxidase (MAO)
Mastication muscles, 179–180, 187
Mayo Clinic, 69, 78
MDA. See Muscular Dystrophy Association (MDA)
MDD (major depressive disorder). See Depression
Mechanical insufflation/exsufflation (MIE), 17
Medical history, 158–159, 176, 185
Medical management. See also Medications; Speech and swallowing examination; Surgery
of Huntington’s disease, 126
of Parkinson’s disease, 77–80, 81
Medicare, 40–41
Medications
for amyotrophic lateral sclerosis (ALS), x, 6–7
disease-modifying therapy with, 152
for Huntington’s disease, x
for multiple sclerosis, x, 152
for Parkinson’s disease, x, 77–79, 83, 90–91
for saliva management, 51–52
for speech disorders (dysarthria), 90–91
for swallowing disorders (dysphagia), 107, 109
Memory aids and calendars, 132, 154
Memory problems. See Cognitive problems
MIE. See Mechanical insufflation/exsufflation (MIE)
Mirapex, 78
Mitoxantrone, 152
MNDs. See Amyotrophic lateral sclerosis (ALS); Motor neuron diseases (MNDs)
Monoamine oxidase (MAO), 78
Monoamine oxidase-B, 78
Motor disturbances
  with Huntington’s disease, 122–123
  with multiple sclerosis, 147, 163–164
Motor neuron diseases (MNDs), 1–2. See also Amyotrophic lateral sclerosis (ALS)
Motor neurons, CD
MRI (magnetic resonance imaging), 5, 146–147, 150
MSA. See Multiple system atrophy (MSA)
Multiple sclerosis
  affective disorders with, 150
  age at onset of, x, 146, 151
  alphabet board supplementation for, 163
  associations on, CD
  ataxia and, 153, 157, 161–162, CD
  characteristics of generally, ix
  choking with, 166
  cognitive changes with, x, 148–149, 154
  definition, 145, 224
  diagnosis, 150
  early stages of, 166–167
  employment and, 154–155
  epidemiology of, 146
  fatigue with, 149, 153–155, 167
  functional status of, 150–151
  handout, CD
  heat sensitivity with, 150
  late stages of, 167
  magnetic resonance imaging (MRI) and, 146–147, 150
  medications for, x, 152
  mild dysarthria with, 161–162
  moderate dysarthria with, 161, 162–163
  motor symptoms of, 147, 163–164
  neurological changes with, x, 145
  paced speech for, 162–163
  primary progressive MS, 151
  prognosis of, 151–152
  progression of changing function in, x, 150–152
  progressive-relapsing MS, 151
  references on, 169–173
  rehabilitation for, 153–155
  relapsing-remitting MS, 149, 151
  respiratory pattern stabilization program for, 162
  respiratory patterning for, 163
  risk factors for, 146
  secondary progressive MS, 151
  sensory symptoms of, 148, 155
  severe dysarthria with, 161, 163–164
  signs and symptoms of, x, 147–150, 153, CD
  sites of central nervous system (CNS) lesions and impairment in, 147, 150
  spasticity with, 147, 153, 156–157, 162
  speech assessment issues for, 158–160
  speech characteristics associated with, 156
  speech disorders with, x, 156–164, CD
speech treatment for, 160–164, CD
swallowing difficulty management for, 166–167
swallowing disorders with, x, 165–167, CD
visual-motor problems with, 163–164
vocabulary selection for, 164

Multiple system atrophy (MSA), 69, 73–74, 82, 86
Muscle cramping and spasms, 8
Muscular Dystrophy Association (MDA), CD

Naming, 124
Nasal emission, 224
Nasogastric tube, 224
Natalizumab, 152
National Institute of Neurological Disorders and Stroke (NINDS), 7, CD
National Multiple Sclerosis Society, 152, CD
National Parkinson Foundation (NPF), CD
NINDS. See National Institute of Neurological Disorders and Stroke (NINDS)
NIV. See Noninvasive ventilation (NIV)
Noninvasive ventilation (NIV), 15–17
Normal eating habits, 45
Normal speech production, 31–32, CD
Normal swallowing, CD
Nothing by mouth. See NPO (nothing by mouth)
Noventrone, 152
NPO (nothing by mouth)
  ALS Severity Scale and, 27
definition, 224
dysphagia and, 49

Occupational therapy, 81
Oculogyric crisis, 224
Olivopontocerebellar atrophy (OPCA), 74
On-off effect, 224
OPCA. See Olivopontocerebellar atrophy (OPCA)
Organizations and associations, CD

Paced speech, 162–163
Pacing board, 102
Palatal lift prosthesis, 35, 224
Palate, 179–180, 187
Palilalia, 102, 224
Palliative care, 9–10
Pallidotomy, 79, 91
Paralysis agitans, 224
Parkinson Alliance, CD
Parkinson plus syndromes, 69, 73–75, 86
Parkinson’s disease
  age at onset of, x
  associations on, CD
  behavioral intervention (speech treatment) for, 91–95
  characteristics of generally, ix
  cognitive problems with, x, 81–82, CD
  compared with Parkinson plus syndromes, 69, 73–75, 86
  compared with progressive supranuclear palsy (PSP), 69, 74–75, 86, 105–106, 224
definition, 69, 224
depression with, 80–81, 82
diagnosis, 73
feeding and dietary modifications for, 109
handout, CD
Hoehn and Yahr Functional Rating Scale for, 75–76
idiopathic Parkinson’s disease, 69
incidence of, 69
language deficits with, 82
medical management of, 77–80
medications for, x, 77–79, 83
natural course of, x
neurological changes with, x, 70–71
problems associated with, 80–83
progression of dysarthria with, 88–90
rate of progression of, 75–77
references on, 111–119
rehabilitation for, 80, 81
respiratory problems with, 82–83, 86–87, 97
secondary or acquired Parkinson’s disease, 69
sensitivity of clinical signs of, 73
signs and symptoms of, x, 71–73, CD
specificity of clinical signs of, 73, 84–102
speech characteristics associated with, 84–86
speech disorders with, x, 84–102, CD
speech scale for, 90
speech treatment for, 90–102, CD
surgery for, 79–80, 91
swallowing disorders management for, 107–109
swallowing disorders with, x, 103–109, CD
Unified Parkinson’s Disease Rating Scale (UPDRS), 76, 77
Parkinson’s Disease Foundation (PDF), 78, CD
Parlodiel, 78
Patient autonomy. See Autonomy of patients
Patient’s history, 175–177, 185
PBP. See Progressive bulbar palsy (PBP)
PDF. See Parkinson’s Disease Foundation (PDF)
Peak expiratory cough flow (PECF), 14, 17
PECF. See Peak expiratory cough flow (PECF)
PEG. See Percutaneous endoscopic gastrostomy (PEG)
Percutaneous endoscopic gastrostomy (PEG), 14, 44, 48, 109, 224
Peripheral nervous system, 224
Pharmacological intervention. See Medications
Pharyngeal constrictors, 179–180, 187
Phonation
  with amyotrophic lateral sclerosis (ALS), 181
definition, 224
  with Parkinson’s disease, 87, 96–99
  sustained phonation measure, 160
Phonatory instability, 224
Physical examination. See Speech and swallowing examination
Physical therapy, 81
PLS. See Primary lateral sclerosis (PLS)
PMA. See Primary progressive muscular (spinal) atrophy (PMA)
Portable writing systems, 37
Postural instability, 71–73
Pramipexole, 78
Prevalence, definition of, 224
Primary lateral sclerosis (PLS), 2
Primary progressive muscular (spinal) atrophy (PMA), 2
Procedural memory, 224
Progressive bulbar palsy (PBP), 2
Progressive supranuclear palsy (PSP), 69, 74–75, 86, 105–106, 224
PSP. See Progressive supranuclear palsy (PSP)
Psychological services and counseling, 81. See also Affective disorders
Pulmonary function tests, 15, 182, 224

Randomly selected sentences, 160
Rate-control techniques for Parkinsonian dysarthria, 100–101
Rating scales
  Dysphagia Severity Rating Scale, 107, 108
  Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
  for Parkinson’s disease, 75–77, 99
  for speech characteristics in Parkinson’s disease, 99
  Swallowing Performance Scale, 166
Reading of a standard passage, 160
Reading of randomly selected sentences, 160
Rebif, 152
Recording of conversation, 199, 208–209, 215–217
Rehabilitation
  for amyotrophic lateral sclerosis (ALS), 7–10
  exercise and, 7–8
  goals of, 7
  for multiple sclerosis, 153–155
  palliative care and, 9–10
  for Parkinson’s disease, 80, 81
  patient autonomy and, 8–9
Rehabilitation Engineering Research Center on AAC (AAC-RERC), CD
Remissions, CD
Remotivation therapy, 134
Requip, 78
Respiration, 224. See also Respiratory problems
Respiratory pattern stabilization program, 162
Respiratory patterning, 163
Respiratory problems
  with amyotrophic lateral sclerosis (ALS), 12–17, 43–44
  assessment of, 14–15, 43–44
  assistive ventilatory, 15–16
  examination of respiratory muscles, 181–182, 187
  management of, 15–17
  with multiple sclerosis, 161–164
  with Parkinson’s disease, 82–83, 86–87, 97
  respiratory chorea with Huntington’s disease, 124
  speech production and, 86–87, 97
  swallowing disorders and, 43–44
Respiratory pump muscles, 181–182
Respiratory valve muscles, 182
Respirometer, 182, 224
Resting tremor, CD, 71–72, 224
Rigid syndrome, 71
Rigidity
  definition, 225
  with Huntington’s disease, 122
  with Parkinson’s disease, 71–73, CD
Riluzole, 6
Ropinirole, 78
Saliva management, 49–52, CD
Scanning speech, 156
Secondary or acquired Parkinson’s disease, 69
Selegiline, 78–79
Sensitivity of clinical signs of Parkinson’s disease, 73
Sensory symptoms of multiple sclerosis, 148, 155
Shy–Drager syndrome, 74, 86
SLPs. See Speech–language pathologists (SLPs)
SND. See Striatonigral degeneration (SND)
Social interaction. See Conversation and interaction
Spastic dysarthria, 86, 225
Spasticity
  with amyotrophic lateral sclerosis (ALS), CD
definition, 225, CD
  with multiple sclerosis, 147, 153, 156–157, 162
Specificity of clinical signs of Parkinson’s disease, 73
Speech and swallowing examination
  of buccal/frontal/orbital muscles, sternocleidomastoid/trapezius muscles, and vocal folds, 180–181
current health care management, 176–177, 186
diadochokinetic rates, 160, 177–179, 222
form for, 185–188
for Huntington’s disease, 136
Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
medical history, 176, 185
for multiple sclerosis, 160
of palate, muscles of mastication, pharyngeal constrictors, and buccinators, 179–180, 187
for Parkinson’s disease, 95, 107
patient’s history, 175–177, 185
physical examination, 177–182, 186–187
reading of a standard passage, 160
reading of randomly selected sentences, 160
references on, 193–194
of respiratory muscles, 181–182, 187
speech function assessment, 183, 187, 189–190
sustained phonation, 160
Swallowing Disorders Interview Worksheet, 191
swallowing function assessment, 183–184, 187–188, 191
of tongue and lips, 177–179, 186
Speech disorders (dysarthria). See also Conversation and interaction; Language deficits; Speech and swallowing examination; Speech production; Speech treatment
  with amyotrophic lateral sclerosis (ALS), x, 18–41, CD
articulation and, 87, 88
assessment of, in clinical examination, 183, 187, 189–190
assessment of Parkinsonian dysarthria, 95, 99
assessment of, with ALS Severity Scale, 25–26, 55
assessment of, with multiple sclerosis, 158–160
ataxia and, 153, 157, 161–162, CD
compensation strategies for, CD
definition of dysarthria, 222, CD
handout, CD
with Huntington’s disease, x, 124, 126, 127–134, CD
impact of, on conversations, 196–197
medications for, 90–91
mild dysarthria and cognitive change with Huntington’s disease, 128–129
mild dysarthria with multiple sclerosis, 161–162
mild Parkinsonian dysarthria, 96–99
moderate dysarthria and cognitive change with Huntington’s disease, 129–130
moderate dysarthria with multiple sclerosis, 161, 162–163
moderate Parkinsonian dysarthria, 96, 99–101
with multiple sclerosis, x, 156–164, CD
with Parkinson plus syndromes, 86
with Parkinson’s disease, x, 84–102, CD
phonation and, 87, 96–99
rate of progression of, in Parkinson’s disease, 88–90
rate of speech changes in ALS, 20, 22–24
respiration and, 86–87
scanning speech, 156
severe dysarthria with Huntington’s disease, 129, 130–134
severe dysarthria with multiple sclerosis, 161, 163–164
severe Parkinsonian dysarthria, 96, 101–102
spasticity and, 156–157, 162
speech intelligibility related to other variables in ALS, 20, 21–22
speech rate and, 87, 88
stages of, 25–26
velopharyngeal function and, 87, 88
Speech-generating devices, 102
Speech intelligibility, 225
Speech–language pathologists (SLPs), 196–197
Speech production. See also Speech disorders (dysarthria)
articulation and, 87, 88
components of, in Parkinson’s disease, 86–88
handout, CD
normal speech processes with amyotrophic lateral sclerosis (ALS), 31–32
normal speech production, CD
phonation and, 87, 96–99
respiration and, 86–87, 97
speech rate, 87, 88
structures for, CD
velopharyngeal function and, 87, 88
Speech rate with Parkinson’s disease, 87, 88
Speech rate with Parkinson’s disease, 87, 88
Speech rate with Parkinson’s disease, 87, 88
Speech treatment. See also Augmentative communication system (AAC)
alphabet boards and alphabet board supplementation, 37, 102, 131–132, 163, 221
for amyotrophic lateral sclerosis (ALS), 29–41, CD
behavioral intervention for, 91–95
behavioral modifications and, 31, 34–36
behavioral rate-control techniques, 100–101
calendars and memory aids, 132, 154
communication for patients on ventilators, 41
conversation starters, 132–133
delayed auditory feedback (DAF), 101
for detectable speech disturbance, 31, 32–34
eye-gaze systems, 41
for Huntington’s disease, 128–134, CD
Lee Silverman Voice Treatment (LSVT), 80, 98–99
loss of useful speech and, 41
making choices, 132
for mild dysarthria and cognitive change with Huntington’s disease, 128–129
for mild dysarthria with multiple sclerosis, 161–162
for mild Parkinsonian dysarthria, 96–99
for moderate dysarthria and cognitive change with Huntington’s disease, 129–130
for moderate dysarthria with multiple sclerosis, 161, 162–163
for moderate Parkinsonian dysarthria, 96, 99–101
for multiple sclerosis, 161–164, CD
natural speech with supportive partners, 131
normal speech processes and, 31–32
paced speech, 162–163
pacing board, 102
for Parkinson’s disease, 81, 90–102, CD
principles for intervention, 29–30
respiratory pattern stabilization program, 162
respiratory patterning, 163
for severe dysarthria with Huntington’s disease, 129, 130–134
for severe dysarthria with multiple sclerosis, 161, 163–164
for severe Parkinsonian dysarthria, 96, 101–102
speech-generating devices, 102
staging of intervention, 30–41
“theater voice,” 100
visual-motor problems with multiple sclerosis, 163–164
vocabulary selection and, 164
voice amplifiers, 101
yes/no systems, 41, 133–134, 139
Spinemet, 225
Spinobulbar muscular atrophy (Kennedy disease), 1, 2
Spirantization, 225
Sternocleidomastoid/trapezius muscles, 180–181
Steroids, 152
Strained-strangled voice, 225
Striatonigral degeneration (SND), 74
Subchoreatic state of Huntington’s disease, 122
Substantia nigra, CD
Surgery. See also Tube feeding
  for aspiration management, 53–54
  for Parkinson’s disease, 79–80, 91
  for saliva management, 52
  for speech disorders with Parkinson’s disease, 91
  for swallowing disorders with ALS, 52, 53–54
Sustained phonation, 160
Swallow apnea, 43
Swallowing. See also Speech and swallowing examination; Swallowing disorders; Swallowing disorders management
correct and incorrect positions for, 46, CD
double swallow, 46
neck flexion position for, 46
normal swallowing, CD
stages of, 225, CD
Swallowing disorders (dysphagia). See also Speech and swallowing examination; Swallowing disorders management
with amyotrophic lateral sclerosis (ALS), x, 42–54, CD
assessment of, in clinical examination, 183, 187–188, 189–190
assessment of, with ALS Severity Scale, 26–27, 42, 43–44, 56
assessment of, with Huntington’s disease, 135–137
assessment of, with Parkinson’s disease, 106–107
definition, 222
eye early eating problems and, 45, 46–47
esophageal stage difficulties, 136, 137, CD
handouts, CD
with Huntington’s disease, x, 135–138, CD
interview worksheet for assessment of, 191
with multiple sclerosis, x, 165–167, CD
oral preparatory and oral stage difficulties, 136, 137, CD
with Parkinson’s disease, x, 81, 103–109, CD
pharyngeal stage difficulties, 136, 137, CD
with progressive supranuclear palsy (PSP), 105–106
rate of progression of, in ALS, 42–43
respiratory problems and, 43–44
Severity Rating Scale for, 107, 108
slowed eating due to, CD
stages of, 26–27
swallow apnea, 43
symptoms of, with Parkinson’s disease, 104–105
warning signs of, 184, CD

Swallowing disorders management
for amyotrophic lateral sclerosis (ALS), 44–49
aspiration management, 52–54
assistive devices for, 138
compensation strategies, 109, CD
dietary changes for, 27, 47–48, 109, 138, CD
double swallow, 46
for Huntington’s disease, 137–138
liquid intake, 46, 47–48
medications, 107–108
for multiple sclerosis, 166–167
normal eating habits, 45
NPO (nothing by mouth), 27, 49
for Parkinson’s disease, 107–109
postural and positional changes for, 137–138
saliva management, 49–52, CD
staging of intervention, 45–49
supervision to control eating rate and bite size for, 138
tube feeding, 46–47

Tasmar, 79
Telephone communication, 37
Thalamotomy, 79, 91
“Theater voice,” 100
TIV. See Tracheostomy invasive ventilation (TIV)
Tolcapone, 79
Tongue, 177–179, 186
Tracheal diversion, 54
Tracheoesophageal anastomosis, 17
Tracheostomy, 225
Tracheostomy invasive ventilation (TIV), 16
Treatment. See Medications; Speech treatment; Surgery
Tremor
definition, 225
“intention” tremor in multiple sclerosis, 147, 153, 155
Parkinson’s disease and, 71–73
resting tremor, CD
Trihexyphenidyl, 79
Tube feeding
ALS Severity Scale and, 27
definition of nasogastric tube, 27, 224
intervention strategies, 48
management of, 49
PEG (percutaneous endoscopic gastrostomy) for, 14, 44, 48, 109, 224
symptoms indicating need for, 48
timing of, 48–49
Tysabri, 152
Unified Parkinson’s Disease Rating Scale (UPDRS), 76, 77
University of Nebraska AAC Center, 38
UPDRS. See Unified Parkinson’s Disease Rating Scale (UPDRS)
Upper extremity function
  assessment of, with ALS Severity Scale, 27–29, 58
  definition, 225
Upper motor neurons, 225, CD

Velopharyngeal function, with Parkinson’s disease, 87, 88
Velopharyngeal mechanism, definition, 225
Ventilators, 41, 225
Ventilatory assistance, 15–17
Video recording of conversation, 199, 208–209, 215–217
Vital capacity, 182, 225
Vocabulary selection, 164
Vocal fold closure, 54
Vocal folds, 180–181
Voice amplifiers, 101

Weakness
  in amyotrophic lateral sclerosis (ALS), 3, 7, 8
  definition of, 225
  in multiple sclerosis, 147, 153, 155
Web sites, CD
Westphal’s variant of Huntington’s disease, 122
WHO. See World Health Organization (WHO)
Workplace. See Employment
World Federation of Neurology Research Group on Neuromuscular Disease, 5
World Health Organization (WHO), 130

Yes/no systems, 41, 133–134, 139